Contracts › W911SR26CA003
W911SR26CA003: The Purpose of This Small Business Innovation Research (SBIR) Phase Ii Contract Is to Show Efficacy of Anti-Viral Treatment With the Pvx Therapeutic.
Awarded to Cygnos Biotech, Llc by Department of the Army.
$1.4Mobligated
$1.4Mpotential value
01 August 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | W911SR26CA003 |
|---|---|
| Awardee | Cygnos Biotech, Llc |
| Awarding agency | Department of the Army |
| Awarding office | W6QK ACC-APG |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AC12 National Defense R&D Services; Department of Defense - Military; Applied Research |
| Place of performance | FL |
| Offers received | 1 |
| Period of performance | 02 February 2026 to 01 August 2027 |
| Potential end | 01 August 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record